Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Silvia Ferrari

6PUBLICATIONS

29CO-AUTHORS

Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Mar 26, 2024

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz

|Mar 10, 2023

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.

Armando Santoro, Alison J Moskowitz, Silvia Ferrari

|Oct 26, 2022

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.

Anas Younes, John M Burke, Bruce D Cheson

|May 25, 2022

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.

Lydia Scarfò, Silvia Ferrari, Anna Maria Frustaci

|Jan 19, 2021

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.

Silvia Ferrari, Chiara Caprioli, Alessandra Weber

|Apr 25, 2020

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.

Leo I Gordon, Jason B Kaplan, Rakesh Popat

Pageof 1

Frequent Collaborators

2 joint publications

Kerry J Savage

2 joint publications

Armando Santoro

1 joint publications

Leo I Gordon

1 joint publications

Giuseppe Gritti

1 joint publications

Dima El-Sharkawi

1 joint publications

Ian Chau

1 joint publications

Jaime Pérez de Oteyza

1 joint publications

Kate Stumpo

1 joint publications

David Cunningham

1 joint publications

Francesc Bosch

Frequent Collaborators

2 joint publications

Kerry J Savage

2 joint publications

Armando Santoro

1 joint publications

Leo I Gordon

1 joint publications

Giuseppe Gritti

Top Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on : Feb 10, 2023

See more related videos

Top Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on : Feb 10, 2023

See more related videos